BIA
BCRX icon

BHK Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

BHK Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Hold
15,000
– – 0.04% 79
2026
Q1 		$143K Buy
+15,000
New +$116K 0.05% 79

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BHK Investment Advisors's BCRX Position: Q2 2026 in Review

BHK Investment Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 15,000 shares worth $150K. The position accounts for 0.04% of the portfolio, ranked #79.

BHK Investment Advisors first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • BHK Investment Advisors held 15,000 shares of BioCryst Pharmaceuticals worth $150K as of Q2 2026.
  • BHK Investment Advisors left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.04% of BHK Investment Advisors's portfolio in Q2 2026, its #79 holding.
  • BHK Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on BHK Investment Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.